This site is intended for health professionals only

Sunday 21 July 2019
Share |

Topic: new medicines

March 26, 2015
The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost effectiveness of new drugs; this hampers the value-assessment and decision-making processes.

The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost–effectiveness of new drugs; this hampers the value-assessment and decision-making processes.